MNOV volume alertEarly alert on this stock. Volume is all right, just looking for a price action. The chart pattern is good.
Next report date
Report period
Q1 2024
EPS estimate
−0.05EUR
Revenue estimate
—
−0.158EUR
−7.77 MEUR
906.01 KEUR
46.48 M
About MediciNova, Inc.
Sector
CEO
Yuichi Iwaki
Headquarters
La Jolla
Website
Employees (FY)
13
Founded
2000
FIGI
BBG004LZGZ96
MediciNova, Inc. is a biopharmaceutical company, which engages in the acquisition and development of small molecule therapeutics for the treatment of diseases with unmet medical needs. The company was founded by Yuichi Iwaki on September 26, 2000, and is headquartered in La Jolla, CA.
MediciNova Announces Positive Top-Line ResultsMNOV: MediciNova, Inc.
2022-06-08 06:30:00
MediciNova Announces Positive Top-Line Results from Phase 2 Clinical Trial of MN-166 (ibudilast) in Hospitalized COVID-19 Patients at Risk for Acute Respiratory Distress Syndrome
Vaccine Joint Development with BioComo and Mie University JapanMediciNova Announces SARS-CoV-2 Vaccine Joint Development with BioComo and Mie University Japan
through our joint development with MediciNova, we will proceed with further non-clinical and clinical trial development as quickly as possible globally and not only in Japan.
We are confident that the B
$MNOV can rise in the next daysContextual immersion trading strategy idea.
The demand for shares of MediciNova looks higher than the supply.
The company focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs.
Due to the spread of COVID-19, the demand for the c
MNOV TECHNICAL ANALYSIS Bearish until bullish, chart looks strong. Upon break of CTL (counter trend line) look for Long opportunities.
pennies to thousands candidaterelative strength good
macd about to cross
cci and percent r good
above 50 ma
cmf going up
j hook pattern
biotech
long base
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on BER exchange MEDICINOVA NEW DL-,001 stocks are traded under the ticker RMN.
MEDICINOVA NEW DL-,001 is going to release the next earnings report on May 10, 2024. Keep track of upcoming events with our Earnings Calendar.
RMN earnings for the last quarter are −0.01 EUR per share, whereas the estimation was −0.08 EUR resulting in a 87.50% surprise. The estimated earnings for the next quarter are −0.07 EUR per share. See more details about MEDICINOVA NEW DL-,001 earnings.
Yes, you can track MEDICINOVA NEW DL-,001 financials in yearly and quarterly reports right on TradingView.
RMN net income for the last quarter is −1.87 M EUR, while the quarter before that showed −684.05 K EUR of net income which accounts for −172.72% change. Track more MEDICINOVA NEW DL-,001 financial stats to get the full picture.
No, RMN doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, RMN shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade MEDICINOVA NEW DL-,001 stock right from TradingView charts — choose your broker and connect to your account.
As of May 3, 2024, the company has 13.00 employees. See our rating of the largest employees — is MEDICINOVA NEW DL-,001 on this list?
We've gathered analysts' opinions on MEDICINOVA NEW DL-,001 future price: according to them, RMN price has a max estimate of 25.92 EUR and a min estimate of 25.92 EUR. Watch RMN chart and read a more detailed MEDICINOVA NEW DL-,001 stock forecast: see what analysts think of MEDICINOVA NEW DL-,001 and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. MEDICINOVA NEW DL-,001 EBITDA is −8.86 M EUR, and current EBITDA margin is −988.00%. See more stats in MEDICINOVA NEW DL-,001 financial statements.